The outcome of COVID-19 in patients with hematological malignancy.
Pınar CömertMurat AlbayrakMesut TığlıoğluHacer Berna Afacan ÖztürkMerih Reis ArasBuğra SağlamSenem MaralPublished in: Memo (2021)
It should be kept in mind that low hemoglobin and platelet levels contribute to mortality. In addition, it is important to protect patients with hematological cancer from COVID-19 and undertake effective vaccination due to its mortal course.